Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript

Azenta, Inc. (AZTA) reported Q3 2025 revenue of $144 million, flat year-over-year on a reported basis and down 2% organically, with non-GAAP EPS at $0.19. Despite macro headwinds, the company achieved significant adjusted EBITDA margin expansion of 260 basis points to 12.3%, driven by operational improvements and cost discipline. While Sample Management Solutions (SMS) revenue declined 6% organically due to customer capital investment delays, its gross margin improved substantially, partially offset by Multiomics' lower gross margin despite 3% organic growth led by strong next-generation sequencing (NGS) momentum. Azenta reaffirmed its full-year 2025 organic revenue growth guidance of 3-5% and 300 basis points of adjusted EBITDA margin expansion, maintaining a strong financial position with $550 million in cash and no debt, and a robust M&A funnel focused on core accretive opportunities.

Analysis

Azenta, Inc. reported mixed fiscal Q3 2025 results, characterized by soft revenue but significant profitability improvements amidst a challenging macroeconomic environment. Revenue was $144 million, representing a 2% organic decline year-over-year, as strength in next-generation sequencing (NGS) and sample storage was offset by weakness in core products due to customer delays in capital equipment spending. Despite the top-line pressure, the company demonstrated strong operational execution, expanding adjusted EBITDA margin by 260 basis points to 12.3%, driven by cost discipline and efficiencies from its Azenta Business System (ABS) initiative. Segment performance diverged: the Sample Management Solutions (SMS) segment saw revenue decline 6% organically but achieved a 760 basis point expansion in non-GAAP gross margin to 53.6% due to a favorable mix and cost management. Conversely, the Multiomics segment grew 3% organically, led by sustained double-digit volume growth in NGS, but its non-GAAP gross margin compressed by 500 basis points to 42.6% due to an unfavorable product mix. Management reaffirmed its full-year guidance for 3-5% organic growth and 300 basis points of adjusted EBITDA margin expansion, implying a significant revenue acceleration in Q4, supported by a robust product funnel and a multi-million dollar order that shifted from Q3. The company maintains a strong balance sheet with $550 million in cash and no debt, positioning it for strategic tuck-in M&A.

Key Decisions for Investors

• Investors should focus on the company's ability to deliver the implied Q4 revenue step-up to approximately $160 million, as execution on the stated order funnel is critical to validating the reaffirmed full-year guidance and near-term growth outlook.
• The primary consideration is whether the impressive operational improvements and margin expansion, up 260 basis points year-over-year, can be sustained and provide a durable valuation floor while the company navigates headwinds in customer capital spending.
• Monitor for disciplined capital allocation, as the company's $550 million cash position and robust M&A funnel in core areas like biorepositories and automation present a potential catalyst for accelerating growth through strategic acquisitions.
• Consider the divergent trends within the business, specifically whether the high-margin Sample Management Solutions (SMS) segment can rebound from delayed capital orders and if continued growth in Multiomics' NGS can successfully offset margin pressures from secular declines in older technologies.